Cardiac Metastasis from Myxoid Liposarcoma Managed Successfully with Chemotherapy and Radiotherapy: Case Report and Review of the Literature

Author:

Stergiopoulos Georgios M.1,Siontis Brittany L.2,Petersen Ivy A.3,Houdek Matthew T.4ORCID,Ho Thanh P.2ORCID,Okuno Scott H.2ORCID,Robinson Steven I.12

Affiliation:

1. Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA

2. Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA

3. Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA

4. Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA

Abstract

Background: Liposarcoma, one of the most prevalent sarcoma histologies, is recognized for its tendency for extra-pulmonary metastases. While oligometastatic cardiac disease is rarely reported, it poses a unique challenge as oligometastatic sarcomas are often managed with surgical resection. Case Report: We present a case of a 62-year-old man diagnosed with an oligometastatic myxoid liposarcoma (MLPS) to the heart 19 years after the primary tumor resection from the lower limb. The metastatic mass, situated in the pericardium adjacent and infiltrating the left ventricle, was not managed surgically but with a combination of chemotherapy and radiotherapy. The patient’s disease remains stable to date, for more than 10 years. Literature Review: We conducted a review of the literature to determine the preferred management approach for solitary cardiac metastases of sarcomas. We also conducted an in-depth analysis focusing on reported cases of MLPS metastasizing to the heart, aiming to extract pertinent data regarding the patient characteristics and the corresponding management strategies. Conclusions: Although clinical diagnoses of solitary or oligometastatic cardiac metastases from sarcomas are infrequent, this case underscores the significance of aggressive management employing chemotherapy and radiotherapy for chemosensitive and radiosensitive sarcomas, especially when surgical removal is high-risk. Furthermore, it challenges the notion that surgery is the exclusive therapeutic option leading to long-term clinical benefit in patients with recurrent sarcomas.

Publisher

MDPI AG

Reference76 articles.

1. WHO Classification of Tumours Editorial Board (2020). Soft Tissue and Bone Tumours, International Agency for Research on Cancer. [5th ed.]. Publication of the WHO Classification of Tumours.

2. Zafar, R., and Wheeler, Y. (2023). Liposarcoma. StatPearls, StatPearls Publishing LLC.

3. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition;Jo;Pathology,2014

4. The 2020 WHO Classification of Soft Tissue Tumours: News and perspectives;Sbaraglia;Pathologica,2021

5. Liposarcomas in young patients: A study of 82 cases occurring in patients younger than 22 years of age;Alaggio;Am. J. Surg. Pathol.,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3